No headlines found.
Globe Newswire (Wed, 1-Apr 8:00 AM ET)
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Tue, 31-Mar 8:00 AM ET)
electroCore Expands Intellectual Property Portfolio
Globe Newswire (Mon, 30-Mar 8:00 AM ET)
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Globe Newswire (Thu, 19-Mar 4:05 PM ET)
electroCore to Participate at the 38th Annual Roth Conference
Globe Newswire (Tue, 10-Mar 8:00 AM ET)
Globe Newswire (Mon, 9-Mar 8:00 AM ET)
Globe Newswire (Wed, 21-Jan 8:00 AM ET)
Globe Newswire (Tue, 20-Jan 8:00 AM ET)
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
Electrocore trades on the NASDAQ stock market under the symbol ECOR.
As of April 2, 2026, ECOR stock price climbed to $6.80 with 132,001 million shares trading.
ECOR has a beta of 1.75, meaning it tends to be more sensitive to market movements. ECOR has a correlation of 0.10 to the broad based SPY ETF.
ECOR has a market cap of $54.97 million. This is considered a Micro Cap stock.
Last quarter Electrocore reported $9 million in Revenue and -$.34 earnings per share. This beat revenue expectation by $20,202 and exceeded earnings estimates by $.03.
In the last 3 years, ECOR traded as high as $19.49 and as low as $3.83.
The top ETF exchange traded funds that ECOR belongs to (by Net Assets): VTI, VXF, IWC.
ECOR has underperformed the market in the last year with a price return of +9.9% while the SPY ETF gained +18.2%. However, in the short term, ECOR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +51.6% vs -3.6% return in SPY. But in the last 2 weeks, ECOR shares have been beat by the market, returning -1.4% compared to an SPY return of -0.6%.
ECOR support price is $6.04 and resistance is $7.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ECOR shares will trade within this expected range on the day.